

15. (new) The method of claim 10, wherein the administering is by expression of a nucleic acid.
16. (new) The method of claim 10, wherein the wound is an acute wound.
17. (new) The method of claim 10, wherein the wound is a chronic wound.
18. (new) The method of claim 10, wherein the wound is a chronic ulcera.
19. (new) The method of claim 10, wherein the wound is a cutaneous wound.
20. (new) The method of claim 19, wherein the cutaneous wound is from skin loss from burn.
21. (new) The method of claim 10, wherein the wound is a non cutaneous wound.
22. (new) The method of claim 21, wherein the non cutaneous wound is from injury to a stromal tissue.
23. (new) The method of claim 21, wherein the non cutaneous wound is from a surgery.
24. (new) The method of claim 23, wherein the surgery is an abdominal surgery.
25. (new) The method of claim 23, wherein the surgery is a cartilage or a joint surgery.
26. (new) The method of claim 23, wherein the surgery is an oral surgery.

REMARKS

Applicants elect Group III. (Claim 10) without traverse. This claim is directed to a method for treating an individual suffering from a wound comprising administering a cytokine to accelerate wound healing.

In addition, Applicants select lymphotactin among the species of cytokines and cytokine receptors listed by the Examiner.

STATUS OF CLAIMS

Claims 1-9, 11 and 12 are cancelled as they are drawn to non-elected inventions. As a result of the above-mentioned claim cancellations, claim 10 remains pending. Applicants have amended claim 10 for greater clarity and consistency. Support for this claim amendment may be found in the specification (*e.g.*, page 13, lines 7-21) as well as in the originally filed claims.